Beta Drugs
Beta Drugs (BETA) share price was ₹1,976.80 at the 28 Oct 2026 close; market capitalisation ₹2,198 Cr; P/E (TTM) 40.96; sector Healthcare. The share price rose 5.6% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Sep 2026 quarter, revenue rose 33.0% year on year to ₹137.5 Cr and net profit was ₹19 Cr, against ₹12 Cr a year earlier (compared with Sep 2025). Promoters held 58.91% of Beta Drugs in Sep 2026, down 0.19 percentage points from Jun 2026. Its Tapetide Score is 46/100 (Average) as of 28 Oct 2026.
Key Fundamentals
MicrocapPharmaceuticals & BiotechnologyHealthcarePrice-based figures as of 29 Oct 2026, 10:54 IST · EPS basis: Consolidated · TTM
Peer Comparison
Healthcare › Pharmaceuticals
| ₹1,765.90 | 35.03 | 4,23,699 Cr | 5.07 | 0.91% | 13.79% | 17.94% | 61,848 Cr | 12,117 Cr | |
| ₹9,653.50 | 87.62 | 2,56,270 Cr | 15.29 | 0.32% | 15.32% | 18.96% | 11,682 Cr | 2,925 Cr | |
| ₹4,595.20 | 72.14 | 1,74,787 Cr | 9.51 | 0.82% | 12.16% | 9.06% | 17,058 Cr | 2,156 Cr | |
| ₹2,190.10 | 108.21 | 1,18,334 Cr | 22.33 | 0.09% | 16.38% | 19.67% | 7,323 Cr | 1,090 Cr | |
| ₹1,181.60 | 26.29 | 1,17,865 Cr | 4.35 | 0.09% | 16.99% | 19.24% | 28,515 Cr | 4,593 Cr | |
| ₹1,337.30 | 34.64 | 1,11,622 Cr | 2.88 | 0.61% | 10.87% | 13.94% | 34,247 Cr | 3,184 Cr | |
| ₹1,363.10 | 32.66 | 1,10,119 Cr | 3.11 | 0.96% | 11.21% | 14.88% | 28,589 Cr | 3,356 Cr | |
| Beta Drugs (this company) | ₹1,968.00 | 40.78 | 2,189 Cr | 5.00 | 0.00% | 16.95% | 17.98% | 453 Cr | 53 Cr |
| Median 8 companies | ₹1,866.95 | 37.91 | 1,18,099 Cr | 5.04 | 0.47% | 14.56% | 17.96% | 22,787 Cr | 3,055 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Data confidence 100/100
Category scores
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
1- Company has reduced debt.
Weaknesses
2- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding has decreased over last 3 years: -7.82%
Technical Indicators
Oscillators
Bullish
Overall
Bullish
Moving Averages
Bullish
Growth Rate
change over 1 year
change over 1 year
change over 1 year
change over 1 year Operating margin 22% · Sep 2026
Quarterly Results
| Particulars | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 88 | 94 | 100 | 103 | 87 | 94 | 126 | 137 |
| Expenses | 70 | 76 | 81 | 82 | 70 | 76 | 98 | 107 |
| Operating Profit | 18 | 17 | 20 | 21 | 17 | 18 | 27 | 30 |
| OPM % | 21% | 18% | 20% | 21% | 19% | 19% | 22% | 22% |
| Other Income | -1 | 2 | 3 | 3 | 2 | 3 | 2 | 2 |
| Interest | 2 | 3 | 3 | 4 | 4 | 4 | 3 | 2 |
| Depreciation | 3 | 4 | 4 | 4 | 4 | 5 | 4 | 5 |
| PBT | 12 | 12 | 16 | 16 | 10 | 12 | 22 | 26 |
| Tax % | 25% | 26% | 25% | 26% | 19% | 24% | 25% | 25% |
| Net Profit | 9 | 9 | 12 | 12 | 9 | 9 | 16 | 19 |
| EPS (₹) | 8.86 | 8.95 | 11.59 | 12.11 | 8.4 | 8.93 | 14.25 | 16.68 |
Profit & Loss
| Particulars | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 51 | 66 | 91 | 116 | 184 | 227 | 296 | 362 | 384 | 444 |
| Expenses | 41 | 54 | 73 | 91 | 141 | 174 | 236 | 287 | 309 | 352 |
| Operating Profit | 9 | 12 | 18 | 25 | 43 | 53 | 60 | 75 | 76 | 92 |
| OPM % | 19% | 18% | 20% | 21% | 23% | 23% | 20% | 21% | 20% | 21% |
| Other Income | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 2 | 11 | 9 |
| Interest | 1 | 1 | 3 | 2 | 2 | 2 | 3 | 7 | 15 | 13 |
| Depreciation | 2 | 3 | 4 | 7 | 7 | 10 | 10 | 13 | 17 | 18 |
| PBT | 7 | 8 | 12 | 16 | 34 | 41 | 49 | 57 | 54 | 70 |
| Tax % | 1% | -2% | 21% | 27% | 28% | 25% | 25% | 26% | 24% | — |
| Net Profit | 7 | 8 | 9 | 12 | 25 | 31 | 36 | 42 | 41 | 53 |
| EPS (₹) | 7.43 | 8.84 | 9.33 | 11.6 | 24.58 | 30.42 | 36.08 | 42.02 | 40.92 | 48.26 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 9 | 9 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 11 |
| Reserves | 24 | 32 | 48 | 59 | 83 | 113 | 148 | 187 | 235 | 427 |
| Borrowings | 8 | 20 | 23 | 17 | 21 | 20 | 15 | 138 | 148 | 49 |
| Other Liabilities | 9 | 22 | 28 | 31 | 45 | 55 | 82 | 101 | 103 | 170 |
| Total Liabilities | 50 | 83 | 107 | 118 | 158 | 198 | 254 | 436 | 496 | 656 |
| Fixed Assets | 13 | 18 | 44 | 40 | 55 | 63 | 65 | 89 | 125 | 220 |
| CWIP | 1 | 15 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 9 |
| Investments | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Other Assets | 35 | 50 | 63 | 74 | 102 | 135 | 190 | 347 | 371 | 427 |
| Total Assets | 50 | 83 | 107 | 118 | 158 | 198 | 254 | 436 | 496 | 656 |
Cash Flow
| Particulars | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Operating | 17 | 0 | 8 | 19 | 30 | 23 | 31 | 36 | 37 |
| Investing | -11 | -21 | -15 | -6 | -22 | -19 | -14 | -36 | -51 |
| Financing | 5 | 12 | 9 | -8 | -1 | -2 | -7 | 118 | -8 |
| Net Cash Flow | 12 | -9 | 2 | 5 | 7 | 2 | 9 | 118 | -22 |
| Free Cash Flow | 9 | -21 | -7 | 13 | 10 | 5 | 19 | -1 | -16 |
| CFO/EBITDA | 181 | 1 | 47 | 75 | 69 | 44 | 52 | 48 | 49 |
Ratios
| Particulars | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 104 | 139 | 128 | 106 | 90 | 101 | 98 | 103 | 113 |
| Inventory Days | 37 | 104 | 102 | 100 | 87 | 106 | 122 | 127 | 159 |
| Days Payable | 81 | 143 | 119 | 127 | 123 | 139 | 145 | 152 | 172 |
| Cash Conversion Cycle | 60 | 100 | 111 | 79 | 53 | 68 | 75 | 79 | 100 |
| Working Capital Days | 50 | 40 | 56 | 76 | 61 | 73 | 80 | 71 | 97 |
| ROCE % | — | 18% | 21% | 22% | 36% | 34% | 33% | 27% | 19% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Beta Drugs insights
68 extracted metrics + investor summaries across FY18–FY27.
Documents
Frequently Asked Questions about Beta Drugs
What does Beta Drugs Ltd do?
Where is Beta Drugs Ltd (BETA) listed?
Which sector does Beta Drugs Ltd belong to?
What is the market capitalisation of Beta Drugs Ltd?
What is the PE ratio of Beta Drugs Ltd?
What is the 52-week high and low of Beta Drugs Ltd?
What is the Return on Equity (ROE) of Beta Drugs Ltd?
Company Information
Beta Drugs Ltd is engaged in manufacturing of a wide range of oncology (anti-cancer) drugs in India. It has operations in the domestic and export markets.[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/BETA.md for Beta Drugs Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.